Profound Medical Corporation (PROF) Actualités

Form F-10 - Registration Statement for Securities of certain Canadian Issuers.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Profound Medical Annual General Meeting of Shareholders Voting Results

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan

– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major...

Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow

TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference

TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...